Clinical Trial Update: A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating repotrectinib in pediatric and young adult patients with ALK, ROS1, or NTRK1-3 alterations in locally advanced or metastat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cns Tumors
• Lymphoma
• Solid Tumors

Drugs mentioned

• Repotrectinib (repotrectinib)

Snippet

Sponsor: Turning Point Therapeutics, Inc. | Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1, Phase 2 | Status: RECRUITING